The goal of the Bristol-Myers Squibb Global Access program is to enable broad access to the company's HIV medicines at no-profit prices in the regions most impacted by HIV and with limited ability to pay, notably sub-Saharan Africa. The Global Access program is based on three essential pillars of activity and policy: 1) no-profit pricing policy; 2) patent policy; and 3) efforts to enable generic manufacturing. Information on the latter two activities can be found below under the heading 'ARV Licensing in Developing Countries'.

In 2001, BMS announced that it would provide all of its HIV medicines at no-profit prices in sub-Saharan Africa, because of the extreme burden of disease there, combined with the region's limited ability to pay for HIV medicines. BMS has also implemented a differential pricing policy globally, to enable collaboration with and support for government activities in regions with high incidence and low ability to pay for HIV medicines.